首页> 外文期刊>The journal of alternative and complementary medicine: research on paradigm, practice, and policy >A feasibility study exploring the role of chinese herbal medicine in the treatment of endometriosis.
【24h】

A feasibility study exploring the role of chinese herbal medicine in the treatment of endometriosis.

机译:探索中草药在治疗子宫内膜异位症中的作用的可行性研究。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Abstract Background: Endometriosis is a common and disabling gynecologic condition affecting between 5% and 15% of women of childbearing age. Conventional medical intervention has unpleasant side-effects, and symptoms frequently return after treatment. Preliminary evidence suggests Chinese herbal medicine (CHM) may contribute to the treatment of endometriosis. Objectives: The aims of this study were to test the feasibility of a novel methodology for investigating individualized decoctions of CHM rigorously and to gather preliminary data on the treatment effect of CHM for a larger definitive trial. Design: This was a 16-week prospective, double blinded, randomized controlled trial of 40 women with laparoscopically confirmed endometriosis. Settings: The trial was conducted at a private CHM clinic in Hove (U.K.) and at a National Health Service outpatient clinic in London (U.K.). Interventions: Participants were initially randomized to either wait-list control (WLC) or treatment groups to receive either individualized CHM decoctions or a therapeutically inert placebo decoction. Outcome measures: Four 10-cm visual analogue scales (VAS) were used to measure menstrual pain, daily pain, and pain on intercourse and bowel movement; these measurements were recorded weekly. The Endometriosis Health Profile-30 (EHP-30) endometriosis-specific quality-of-life questionnaire was completed at the beginning and at the end of the trial. The Measure Yourself Medical Outcomes Profile (MYMOP) a patient-centered health questionnaire was completed monthly. Liver and renal function was measured at 0, 4, 8, and 16 weeks. Results: Twenty-eight (28) women completed the trial. High dropout rates led to the suspension of the WLC. Randomization, double blinding, and allocation concealment was achieved successfully. Adjusted mean differences favored the active treatment in the EHP-30 and MYMOP scores. VAS scores favored the active treatment for relief of menstrual pain and the placebo group for reduction of daily pain. Conclusions: the methodology successfully allowed individualized CHM decoctions to be tested rigorously. There are nonspecific contextual effects from CHM that require further investigation. Provisional data were generated to warrant a larger, more-definitive study.
机译:摘要背景:子宫内膜异位症是一种常见的致残妇科疾病,影响了5%至15%的育龄妇女。常规医学干预具有不良的副作用,并且症状在治疗后经常复发。初步证据表明中草药(CHM)可能有助于子宫内膜异位症的治疗。目的:本研究的目的是检验严格研究CHM个体化汤的新方法的可行性,并收集有关CHM治疗效果的初步数据,以进行较大的明确试验。设计:这是一项为期16周的前瞻性,双盲,随机对照试验,对40例经腹腔镜检查证实为子宫内膜异位的女性进行了研究。地点:该试验在英国霍夫的一家私人CHM诊所和在伦敦(英国)的国家健康服务门诊进行。干预措施:参与者最初被随机分为等待名单对照组(WLC)或治疗组,以接受个体化CHM汤或治疗惰性的安慰剂汤。结果测量:四个10厘米的视觉模拟量表(VAS)用于测量月经疼痛,日常疼痛以及性交和排便疼痛。每周记录这些测量值。在试验的开始和结束时,完成了子宫内膜异位症健康状况30(EHP-30)子宫内膜异位症特异性生活质量调查表。以患者为中心的健康调查表的“衡量您的医疗结果概况”(MYMOP)每月完成一次。在第0、4、8和16周测量肝和肾功能。结果:28(28)名妇女完成了试验。高辍学率导致WLC暂停。成功实现了随机,双盲和隐藏分配。调整后的平均差异有利于积极治疗EHP-30和MYMOP评分。 VAS评分偏向于积极治疗月经痛,而安慰剂组偏向于减轻日常疼痛。结论:该方法成功地使严格的个性化CHM汤得以测试。 CHM存在非特定的上下文影响,需要进一步研究。产生了临时数据以保证进行更大范围,更明确的研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号